MedTrace Logo

Morphine Modulation of The Brain's Pain Matrix

NCT01245244 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-09-21

No results posted yet for this study

Summary

The aim of the current project is to use a model of painful stimulation of skin, muscles and internal organs, where it is possible to measure activity in the brain centers that process pain simultaneously. Magnetic resonance imaging and electroencephalography are combined to optimize the anatomical and physiological description of brain activation. During administration of morphine we will identify how different brain areas are affected. This knowledge will be used to:

1\. Understand the mechanisms of morphine to a greater extent than is possible today, including:

1. to investigate the mechanisms of morphine versus placebo on pain signals in the spinal cord and brain. This is done by a combination of experimental pain models, neurophysiological and imaging techniques (EEG and fMRI). This can be achieved as both subjective and objective measures of the analgesic effect.
2. to examine morphines effect on communication between the centers of the brain that are involved in painprocessing .
3. modeling of morphine pharmacokinetics (the understanding of what the body does to the drug, such as. concentration in the blood and the brain), since this is central to understand the pharmacodynamics (the description of what the drug does to the body and thus the effect it has).
4. to identify biomarkers that can predict whether healthy subjects respond to morphine by experiencing an analgesic effect.

Conditions

Interventions

DRUG

Morphine

Morphine oral mixture

OTHER

orange juice

orange juice

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Anne E Olesen, PhD · Aalborg University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245244 on ClinicalTrials.gov